Praxis Precision Medicine enters the final stretch before its June 10 earnings with options defensiveness at a year-long peak — even as short sellers quietly reduce their exposure.
The options market is flashing its most cautious signal of the past 12 months. The put/call ratio hit 6.10 on May 19, the highest reading in the 52-week range and more than three standard deviations above its 20-day average of 4.48. That z-score of 3.16 is a notable jump from the 0.5 reading cited in last week's note — the shift has been abrupt. Demand for downside protection has surged in the last two sessions, with the PCR moving from roughly 4.2 throughout most of May to 5.60 on Monday and 6.10 Tuesday. The move is striking even against a backdrop where puts have always dominated this name.
Short interest tells a meaningfully different story. At 14.7% of the free float, it remains a genuine overhang — but the trend is clearly lower. Shorts have trimmed roughly 4% over the past week, extending a steady retreat from the near-3.9 million share peak in early May. The borrow market remains loose: availability has actually widened sharply, now running at 1,919% — nearly double last week's already-ample level — and cost to borrow has eased to 0.37% annualised, the lowest in the 30-day window. That widening availability reflects lenders putting more stock into the pool, not short covering creating slack. There is no squeeze pressure here. The short score has slipped from 62.3 on May 11 to 60.3 now, consistent with the easing positioning.
The Street remains bullish, with a wide dispersion of views. BTIG reiterated its Buy and $843 target this morning — the second time the firm has done so in six weeks, signalling conviction rather than drift. Truist raised its target to $715 last week following earnings. The bear on the register is Wedbush, which also lifted its Underperform target post-earnings, moving it to $166 from $130. The mean price target of $652 implies roughly 100% upside from $320.61, though the range between the $166 floor and the $1,245 HC Wainwright ceiling reflects just how wide the clinical uncertainty is. Price-to-book has eased modestly over the past month to 8.3x, with the negative P/E and EV/EBITDA ratios typical of a pre-revenue CNS biotech. The bull case centres on Phase 3 POWER1 and EMERALD data readouts plus potential FDA approvals for ulixacaltamide and relutrigine. The bear case rests on capital raise risk and the sheer competitiveness of the CNS space.
Institutional ownership adds an interesting layer. Orbis Investment Management nearly doubled its stake to 8.9% of shares, adding over 1.2 million shares in Q1. Baker Bros. added 1.6 million shares in the same period, lifting its position to 6.3%. FMR added 800,000 shares. Those are specialist healthcare managers making large discretionary moves — not passive rebalancing. The insider trade data is stale (last logged January 12), so no read-through from that quarter.
Across the peer group, the weakness is broad. KROS fell nearly 15% on the week, CAPR dropped 14.6%, and IMMX shed 16.9%. PRAX at -6.6% on the week outperformed most of its closest correlated names, suggesting the selloff here is at least partly sector-driven rather than stock-specific.
What to watch: the June 10 earnings print is now three weeks out, and the gap between the surging put/call ratio and the retreating short interest is the central tension — whether options hedging reflects genuine fear of a data or guidance disappointment, or simply mechanical positioning ahead of a catalyst, should become clearer as the date approaches.
See the live data behind this article on ORTEX.
Open PRAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
